These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14724297)

  • 1. "Me-too" products--friend or foe?
    Lee TH
    N Engl J Med; 2004 Jan; 350(3):211-2. PubMed ID: 14724297
    [No Abstract]   [Full Text] [Related]  

  • 2. "Me-too" products--friend or foe?
    Relman AS
    N Engl J Med; 2004 May; 350(20):2100-1; author reply 2100-1. PubMed ID: 15146575
    [No Abstract]   [Full Text] [Related]  

  • 3. Common sense, dollars and cents, and drug-eluting stents.
    Vaitkus PT
    J Am Coll Cardiol; 2006 Jul; 48(2):268-9. PubMed ID: 16843173
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Position paper on the use of drug eluting stents (DES) in percutaneous coronary interventions in patients with coronary heart disease].
    Levenson B; ;
    Z Kardiol; 2003 Jul; 92(7):606-12. PubMed ID: 12883846
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dollars and sense of drug-eluting stents.
    Brophy JM
    CMAJ; 2005 Feb; 172(3):361-2. PubMed ID: 15684119
    [No Abstract]   [Full Text] [Related]  

  • 11. [Are drug-coated stents too expensive?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 Nov; 128(47):2466. PubMed ID: 14658445
    [No Abstract]   [Full Text] [Related]  

  • 12. Sirolimus-eluting coronary stents.
    Sharma S; Bhambi B; Nyitray W
    N Engl J Med; 2002 Oct; 347(16):1285; author reply 1285. PubMed ID: 12393833
    [No Abstract]   [Full Text] [Related]  

  • 13. Sirolimus or paclitaxel drug-eluting stents for treatment of chronic total occlusions of coronary arteries: much ado about very little.
    Hemstreet P; Anderson HV
    J Invasive Cardiol; 2006 May; 18(5):209-10. PubMed ID: 16670447
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic impact of drug-eluting stents on hospital systems: a disease-state model.
    Kong DF; Eisenstein EL; Sketch MH; Zidar JP; Ryan TJ; Harrington RA; Newman MF; Smith PK; Mark DB; Califf RM
    Am Heart J; 2004 Mar; 147(3):449-56. PubMed ID: 14999193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting stents: the panacea for restenosis?
    Lim MC
    Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
    [No Abstract]   [Full Text] [Related]  

  • 16. Paradigm shifts in cardiovascular medicine.
    Holmes DR; Firth BG; Wood DL
    J Am Coll Cardiol; 2004 Feb; 43(4):507-12. PubMed ID: 14975455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
    Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
    Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting coronary stents.
    Bonvini RF; Verin V
    N Engl J Med; 2005 Dec; 353(22):2404-8; author reply 2404-8. PubMed ID: 16320452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.